Purchase this article with an account.
Arnaud George, Jean Paul Bellamy, Maryleine Bocquenet; Evolution of demographics of patients treated with intravitreal injections of ranibizumab in the real-life on a 5 years period. Invest. Ophthalmol. Vis. Sci. 2014;55(13):641.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We reviewed the demographics of our patients treated by intravitreal ranibizumab injections from 2009 to 2013 to evaluate how we can compare our real-life experience to pivotal studies.
We retrospectively reviewed the files of our patients treated by intravitreal ranibizumab, excluding patients less than 50 years old. We collected the age, gender et number of injections from 2009 to 2013 (2013 data will be added in the poster).
Mean age was comprised between 79,6 (2009) and 80,21 (2012) years. Sex ratio was 2,27 in 2009 and 1,47 in 2012. We present the evolution of the number and repartition of injections in graphics. Number of injections grew from 850 in 2009 to 2697 in 2012 (317 % of progression). Mean injection number per patient was almost stable, meaning the growing number of injection was due to a increasing amount of patients (from 268 to 692, 258 %). We note the very important proportion of patients older than 80 (more than 50%).
Our study shows good correlation with previous studies, with a mean age slightly superior. The important proportion of patients older than 80 may make hazardous the extrapolation of the safety results of pivotal studies.
This PDF is available to Subscribers Only